PATTERNS OF INFECTION AND THEIR IMPACT ON THE OUTCOMES OF NEXT- GENERATION B-CELL DEPLETING IMMUNOTHERAPIES IN NON-HODGKIN'S LYMPHOMAS: FINDINGS FROM A MULTICENTER RETROSPECTIVE REAL-LIFE COHORT (SIE 2026) - Oct 6, 2026 - Abstract #DP061; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "158 NHL pts received 195 immunotherapy lines: 108 CAR-T cells (58 Axi-cel, 33 Tisa-cel, 16 Brexu-cel, 1 Li- so-cel), 40 bispecific MoAbs (13 glofitamab, 18 epcoritamab, 9 mosunetuzumab), 26 ADCs (11 anti-CD19 ADC: loncastux- imab, 15 anti-CD79b ADC Polatuzumab with rituximab-ben- damustine), and 21 naked MoAbs (tafasitamab-lenalido- mide). Infections are common in novel immunothera- py for NHL; however, most cases occurred early (<100 days) and were mild-to-moderate and manageable. In R/R NHL pts, the main cause of death remains lymphoma pro- gression."
Retrospective data • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin's Lymphoma • CD79B
|
|
L. Nigri1,2; S. Ragaini1,2; M. Novo4; L. Comba3,5; L. Legato4; M. Bisio4; L. Bertolotti3; M. Clerico1,2; F. Fasano4; E. Boccellato3; F. Cavallo1,2; B. Botto4; C. Castellino3; L. Giaccone1,2; C. Boccomini4; S. Bringhen3; B. Bruno1,2; R. Freilone4; M. Massaia1,3; S. Ferrero1,2; A. Castellino1,3
|